PPT-3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in

Author : conchita-marotz | Published Date : 2016-12-15

SAPPHIREI Phase 3 Treatment Naïve Feld JJ et al N Engl J Med 201437015941603 Source Feld JJ et al N Engl J Med 201437015941603 3D ParitaprevirRitonavir Ombitasvir

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "3D (Paritaprevir-Ritonavir-Ombitasvir + ..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in: Transcript

SAPPHIREI Phase 3 Treatment Naïve Feld JJ et al N Engl J Med 201437015941603 Source Feld JJ et al N Engl J Med 201437015941603 3D ParitaprevirRitonavir Ombitasvir Dasabuvir Ribavirin in GT1. Paritaprevir. -. Ritonavir (. Technivie. ). Prepared by: . David H. Spach, MD. Last . Updated: . July 27, 2015. Background and Dosing. Ombitasvir-Paritaprevir. -. Ritonavir (. Technivie. ) . Ombitasvir-Paritaprevir. -Ritonavir. -Ombitasvir . + Dasabuvir) . + RBV in . GT1. SAPPHIRE-II. Phase . 3. Treatment. . Experienced. Zeuzem. S, . et al. N . Engl. J Med. . 2014;370:1604-14.. Source: . Zeuzem. S, et al. N . OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + RBV. Randomisation*. 1 : . 1. Open-label. 18-70 years. HCV genotype 1. HCV RNA ≥ 10,000 IU/ml. Naïve or pre-treated with PEG-IFN + RBV. HIV infection, on ATV/. OBV/PTV/r . + . DSV . + RBV. OBV/PTV/r + . DSV . + RBV. Randomisation**. 1 : 1. Open-label. 18-70 years. HCV genotype 1. Naïve or pre-treated. Cirrhosis*. Child-Pugh A < 7. HCV RNA ≥ 10,000 IU/ml. Co-formulated . ombitasvir. (OBV)/. paritaprevir. (PTV)/. rironavir. (r) :. 25/150/100 mg QD = 2 tablets. Dasabuvir. (DSV) : 250 mg bid. Objective. SVR. 12. (HCV RNA < 25 IU/ml). TURQUOISE-III . OBV/PTV/r . + . DSV . + RBV. OBV/PTV/r + . DSV . + RBV. Randomisation**. 1 : 1. Open-label. 18-70 years. HCV genotype 1. Naïve or pre-treated. Cirrhosis*. Child-Pugh A < 7. HCV RNA ≥ 10,000 IU/ml. . and Dasabuvir +/- . RBV in . GT1b. PEARL-II. Phase . 3. Treatment. . Experienced. Andreone. P, . et al. . Gastroenterology. 2014;147:359-65.. Source: . Andreone. P, et al. Gastroenterology. 2014;147:359-65.. Paritaprevir. -. Ritonavir. . and . Dasabuvir. +/- RBV in GT1. PEARL-III and PEARL-IV. Phase 3. . Treatment. . Naïve. Ferenci. P, et al. N . Engl. J Med. 2014;370:1983-92.. Source: . Ferenci. . -. Ritonavir . and Dasabuvir . + RBV in . GT1. SAPPHIRE-II. Phase . 3. Treatment. . Experienced. Zeuzem. S, . et al. N . Engl. J Med. . 2014;370:1604-14.. Source: . Zeuzem. S, et al. N . Engl. . and Dasabuvir + RBV in GT1. SAPPHIRE-I. Phase 3. . Treatment. . Naïve. Feld JJ, et al. N . Engl. J Med. 2014;370:1594-1603.. Source: Feld JJ, et al. N . Engl. J Med. 2014;370:1594-1603.. Ombitasvir-Paritaprevir-Ritonavir . Feld JJ. NEJM . 2014;370:1594-1603. SAPPHIRE-I . Study. : . o. mbitasvir/paritaprevir/ritonavir. . + . d. asabuvir. . + . ribavirin. . for genotype 1. Treatment regimens. Co-formulated . ombitasvir. DSV . placebo. Randomisation*. Partial blind. 18-70 years. Chronic HCV infection. Genotype 1 . Treatment-naïve. HCV RNA > 10,000 IU/ml. No cirrhosis. No HBV or HIV co-infection. * Randomisation 1:2 if genotype 1a (PEARL-IV) ; . Prepared by: . Sophie . Woolston. , MD and David H. Spach, MD. Last . Updated: . November 18, 2014. 3D. Background and Dosing. 3D (. Paritaprevir. -Ritonavir-. Ombitasvir. + . Dasabuvir. ). 3D (. Paritaprevir. Ombitasvir + . Dasabuvir) +/- . RBV in . GT1b. PEARL-II. Phase . 3. Treatment. . Experienced. Andreone. P, . et al. . Gastroenterology. 2014;147:359-65.. Source: . Andreone. P, et al. Gastroenterology. 2014;147:359-65..

Download Document

Here is the link to download the presentation.
"3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.